Flexibility Required: Balancing the Interests of Children and Risk in Drug Development for Rare Pediatric Conditions.
作者信息
Porter Kathryn M, Stevens Anne, Wilfond Benjamin S
机构信息
Seattle Children's Hospital and Research Institute.
University of Washington School of Medicine.
出版信息
Am J Bioeth. 2020 May;20(4):116-118. doi: 10.1080/15265161.2020.1730494.
Abstract
摘要
相似文献
1
Flexibility Required: Balancing the Interests of Children and Risk in Drug Development for Rare Pediatric Conditions.所需的灵活性：平衡儿童利益与罕见儿科疾病药物研发中的风险
Am J Bioeth. 2020 May;20(4):116-118. doi: 10.1080/15265161.2020.1730494.
2
Role of Patients and Parents in Pediatric Drug Development.患者及家长在儿科药物研发中的作用
Ther Innov Regul Sci. 2019 Sep;53(5):601-608. doi: 10.1177/2168479018820875. Epub 2019 Jan 20.
3
'Best interests' in paediatric intensive care: an empirical ethics study.儿科重症监护中的“最大利益”：一项实证伦理学研究。
Arch Dis Child. 2017 Oct;102(10):930-935. doi: 10.1136/archdischild-2016-312076. Epub 2017 Apr 13.
4
Balancing competing interests in post-placement adoption custody disputes. How do the scales of justice weigh the rights of biological parents, adoptive parents, and children?平衡安置后收养监护权纠纷中的相互冲突利益。司法天平如何权衡亲生父母、养父母和儿童的权利？
J Leg Med. 1994 Jun;15(2):305-43. doi: 10.1080/01947649409510947.
5
Phenomenology and measurement of circumscribed interests in autism spectrum disorders.孤独症谱系障碍中狭隘兴趣的现象学和测量。
Autism. 2011 Jul;15(4):437-56. doi: 10.1177/1362361310386507. Epub 2011 Mar 31.
6
How are children's best interests expressed during their hospital visit?-An observational study.如何在儿童住院期间表达他们的最大利益？一项观察性研究。
J Clin Nurs. 2021 Dec;30(23-24):3644-3656. doi: 10.1111/jocn.15886. Epub 2021 Jun 2.
7
More on parental living liver donation for children with fulminant hepatic failure: addressing concerns about competing interests, coercion, consent and balancing acts.关于为暴发性肝衰竭儿童进行的父母活体肝移植的更多探讨：解决对利益冲突、胁迫、同意及权衡行为的担忧
Am J Transplant. 2005 Nov;5(11):2619-22. doi: 10.1111/j.1600-6143.2005.01083.x.
8
Impact Of The Priority Review Voucher Program On Drug Development For Rare Pediatric Diseases.优先审评券计划对罕见儿科疾病药物研发的影响。
Health Aff (Millwood). 2019 Feb;38(2):313-319. doi: 10.1377/hlthaff.2018.05330.
9
Participatory Development of a Modular Advance Care Planning Program in Pediatric Palliative Care (MAPPS).参与式开发儿科姑息治疗中的模块化预先医疗指示计划 (MAPPS)。
J Pain Symptom Manage. 2022 Feb;63(2):189-198. doi: 10.1016/j.jpainsymman.2021.09.013. Epub 2021 Sep 29.
10
The legal ethics of pediatric research.儿科研究的法律伦理
Duke Law J. 2007 Dec;57(3):517-624.
引用本文的文献
1
Clearing Muddy Waters: The Need to Reconceptualize Minor Increase over Minimal Risk in Pediatric Rare Disease Research.拨开迷雾：儿科罕见病研究中重新界定“略高于最小风险的微小增加”的必要性
Am J Bioeth. 2020 May;20(4):8-10. doi: 10.1080/15265161.2020.1735868.
本文引用的文献
1
Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial.低剂量白细胞介素-2治疗难治性系统性红斑狼疮：一项研究者发起的单中心1期和2a期临床试验。
Lancet Rheumatol. 2019 Sep;1(1):e44-e54. doi: 10.1016/S2665-9913(19)30018-9. Epub 2019 Aug 28.
2
Ethical Drug Development for Rare Childhood Diseases: When There Are Limited But Promising Data in Adults, How to Choose Between Safety or Efficacy Studies?罕见儿童疾病的伦理药物研发：当成人数据有限但前景乐观时，如何在安全性研究和有效性研究之间做出选择？
Am J Bioeth. 2020 May;20(4):111-113. doi: 10.1080/15265161.2020.1730490.
3
Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus.低剂量白细胞介素-2 治疗可选择性调节系统性红斑狼疮患者的 CD4(+) T 细胞亚群。
Nat Med. 2016 Sep;22(9):991-3. doi: 10.1038/nm.4148. Epub 2016 Aug 8.
4
Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus.低剂量白细胞介素-2 选择性纠正系统性红斑狼疮患者调节性 T 细胞缺陷。
Ann Rheum Dis. 2016 Jul;75(7):1407-15. doi: 10.1136/annrheumdis-2015-207776. Epub 2015 Aug 31.
5
Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE.低剂量白细胞介素-2使一名难治性系统性红斑狼疮患者迅速达到临床缓解
Ann Rheum Dis. 2015 Apr;74(4):791-2. doi: 10.1136/annrheumdis-2014-206506. Epub 2015 Jan 21.
6
A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety.高剂量促红细胞生成素用于极低出生体重儿的I/II期试验：药代动力学与安全性
Pediatrics. 2008 Aug;122(2):383-91. doi: 10.1542/peds.2007-2711.
7
How do institutional review boards apply the federal risk and benefit standards for pediatric research?机构审查委员会如何应用联邦关于儿科研究的风险和收益标准？
JAMA. 2004 Jan 28;291(4):476-82. doi: 10.1001/jama.291.4.476.
Zotero 插件